2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Boston Scientific company profile · medical devices, MedSurg & Cardiovascular · history · financial snapshot · S&P 500 rank #202 · 波士頓科學公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | BSX (NYSE) |
| Company | Boston Scientific Corp. |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment |
| S&P 500 rank (by weight) | #202 · 0.09% (Oct 31, 2026) |
| Sector rank | #25 in Health Care (Oct 31, 2026) |
| Headquarters | Marlborough, Massachusetts |
| Founded | June 29, 1979 (Watertown, Massachusetts; holding company to acquire Medi-Tech) |
| CEO | Michael F. Mahoney (Chairman and Chief Executive Officer) |
| Employees | Approximately 59,000 (FY2025 10-K) |
| Market cap | $60.84B (Oct 31, 2026) |
| SEC filings | EDGAR — CIK 0000885725 |
WHAT IT DOES
Boston Scientific develops, manufactures and markets medical devices for interventional specialties — cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation — with the stated purpose of bringing more accessible, lower-cost, lower-trauma options to patients versus open surgery.
In the fourth quarter of 2025 the company reorganized into two reportable segments: MedSurg (Endoscopy, Urology, Neuromodulation) and Cardiovascular, combining the legacy Cardiology and Peripheral Interventions businesses. Cardiovascular is now two-thirds of sales, led by Electrophysiology net sales of $3,325M in 2025 (from $1,904M in 2024) and Watchman at $1,958M.
FY2025 net sales were $20,074M, up 19.9% from $16,747M, with gross profit of $13,854M and operating income of $3,613M. Research and development expense was $2,052M, about 10% of sales, funding the pipeline behind the electrophysiology and structural-heart growth.
BUSINESS SEGMENTS — FY2025 NET SALES
| Segment | Net sales | Share | YoY |
|---|---|---|---|
| MedSurg | $6.83B | 34.0% | +13.2% |
| Cardiovascular | $13.27B | 66.1% | +22.4% |
| Foreign currency impact | −$0.02B | — | — |
| Total net sales (reported) | $20.07B | 100% | +19.9% |
HISTORY
| Year | Milestone |
|---|---|
| 1979 | Boston Scientific founded June 29, 1979, as a holding company to acquire Medi-Tech, by John Abele and Peter Nicholas |
| 2023 | Mandatory convertible preferred stock automatically converted to common stock (June 1, 2023) |
| 2025 | Fourth-quarter reorganization combines legacy Cardiology and Peripheral Interventions into a single Cardiovascular segment |
| 2025 | Net sales $20,074M (+19.9%); Electrophysiology $3,325M; diluted EPS $1.94 |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Net sales | $20.07B (+19.9% YoY) |
| Gross profit | $13.85B |
| Operating income | $3.61B (vs $2.60B in FY2024) |
| Net income | $2.89B |
| Net income attributable to common stockholders | $2.90B |
| Diluted EPS | $1.94 (vs $1.25 in FY2024) |
| Research and development | $2.05B |
| Fiscal year | Calendar year (ended Dec 31, 2025) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Boston Scientific is the S&P 500’s interventional-device compounder at a 0.09% weight and exactly #25 in Health Care by weight — the boundary of the sector top-25 — with growth now led by electrophysiology rather than its legacy cardiology base.
Its 2025 reorganization into MedSurg and Cardiovascular also simplifies how the index story reads: two segments, two margins, and one question — whether EP growth can sustain a $20B sales base without a new acquisition cycle.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 31, 2026 crawl) · StockAnalysis (market cap — Oct 31, 2026 crawl) |
| Financials | Boston Scientific FY2025 Form 10-K (SEC EDGAR, filed Feb 17, 2026; fiscal year ended Dec 31, 2025) |
| Sector classification | GICS (Health Care Equipment) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | BSX(NYSE) |
| 公司 | Boston Scientific Corp. |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備 |
| 標普500排名(按權重) | #202 · 0.09%(2026 年 10 月 31 日) |
| 板塊內排名 | 醫療保健第 #25(2026 年 10 月 31 日) |
| 總部 | 美國麻薩諸塞州馬爾伯勒 |
| 成立 | 1979 年 6 月 29 日(麻薩諸塞州沃特敦;為收購 Medi-Tech 而設的控股公司) |
| 行政總裁 | Michael F. Mahoney(董事長兼行政總裁) |
| 員工 | 約 59,000(FY2025 10-K) |
| 市值 | $60.84B(2026 年 10 月 31 日) |
| SEC 申報 | EDGAR — CIK 0000885725 |
業務概覽
波士頓科學開發、製造及銷售介入專科醫療器械——心臟科、周邊介入、電生理、內窺鏡、泌尿科與神經調控——宗旨是較開刀手術提供更可及、更低成本、創傷更小的治療選擇。
2025 年第四季公司重組為兩個可報告板塊:MedSurg(內窺鏡、泌尿科、神經調控)與心血管,將原心臟科與周邊介入業務合併。心血管現佔銷售三分之二,其中電生理 2025 年淨銷售 $3,325M(2024 年為 $1,904M),Watchman 為 $1,958M。
FY2025 淨銷售 $20,074M,較 $16,747M 增長 19.9%,毛利 $13,854M,營業利潤 $3,613M。研發開支 $2,052M,約佔銷售 10%,為電生理與結構性心臟增長背後的產品線提供資金。
業務板塊 — FY2025 淨銷售
| 板塊 | 淨銷售 | 佔比 | 同比 |
|---|---|---|---|
| MedSurg | $6.83B | 34.0% | +13.2% |
| 心血管 | $13.27B | 66.1% | +22.4% |
| 外匯影響 | −$0.02B | — | — |
| 淨銷售合計(已報告) | $20.07B | 100% | +19.9% |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1979 | Boston Scientific 於 1979 年 6 月 29 日成立,為收購 Medi-Tech 而設的控股公司,由 John Abele 與 Peter Nicholas 創立 |
| 2023 | 強制可轉換優先股自動轉換為普通股(2023 年 6 月 1 日) |
| 2025 | 第四季重組,將原心臟科與周邊介入業務合併為單一心血管板塊 |
| 2025 | 淨銷售 $20,074M(+19.9%);電生理 $3,325M;攤薄每股盈利 $1.94 |
競爭地位
財務快照 — FY2025
| 淨銷售 | $20.07B(同比 +19.9%) |
| 毛利 | $13.85B |
| 營業利潤 | $3.61B(FY2024 為 $2.60B) |
| 淨利潤 | $2.89B |
| 歸屬普通股股東淨利潤 | $2.90B |
| 攤薄每股盈利 | $1.94(FY2024 為 $1.25) |
| 研發 | $2.05B |
| 財政年度 | 曆年(截至 2025 年 12 月 31 日) |
主要風險
對標普500的重要性
波士頓科學是標普500中的介入器械複合增長股:指數權重 0.09%、醫療保健權重恰為第 #25——板塊前 25 名的邊界——增長現由電生理而非傳統心臟科基盤帶動。
其 2025 年重組為 MedSurg 與心血管亦簡化了指數故事的讀法:兩個板塊、兩個利潤率,以及一個問題——電生理增長能否在不開啟新一輪併購週期的情況下支撐 $20B 銷售基數。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 31 日抓取)· StockAnalysis(市值——2026 年 10 月 31 日抓取) |
| 財務 | Boston Scientific FY2025 Form 10-K(SEC EDGAR,2026 年 2 月 17 日申報;財政年度截至 2025 年 12 月 31 日) |
| 板塊分類 | GICS(醫療保健設備),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-31 11:39 · updated 2026-11-14 23:05 · rev 6